Oregon Drug Price Transparency Reporting: Deadline Extended to April 15, 2026

Oregon's Drug Price Transparency Program has reinstated its annual price increase reporting requirement and the deadline is approaching fast. Here's everything prescription drug manufacturers need to know to stay compliant.

Reporting deadline: April 15, 2026

‍The Oregon Department of Consumer and Business Services extended the original March 15 deadline. Reports must be submitted by April 15, 2026.

What changed?

The Oregon Department of Consumer and Business Services (DCBS) has lifted its temporary suspension of the annual drug price increase reporting requirement. This means manufacturers that previously paused reporting obligations must now resume compliance under the state's Drug Price Transparency Program.

Who needs to file a report?

A report must be submitted for each NDC identified in ORS 646A.689(3) if the drug's average price increased by 10% or more compared to the prior calendar year. "Average price" is defined as the weighted average of the drug's Wholesale Acquisition Cost (WAC) over the calendar year, with each price weighted by the number of days it was in effect.

The 10% threshold — how it's calculated

Manufacturers should compare the weighted average WAC for the most recent calendar year (the reporting year) against the weighted average WAC for the prior calendar year (the comparison year). If the increase equals or exceeds 10%, a report is required for that NDC.

Are you a "reporting manufacturer"?

Prescription drug manufacturers must register with the Drug Price Transparency Program and pay an annual assessment if they meet all three of the following criteria:

1. Required to register with the Oregon Board of Pharmacy as a drug manufacturer
2. Manufactures FDA-approved prescription drugs available for sale in Oregon, as defined in ORS 646A.689(1)(d)
3. Sets or modifies the Wholesale Acquisition Cost (WAC) for those drugs

Note: If affiliated or related entities each independently meet the definition of a reporting manufacturer, their registration obligations may vary. Consult the program's user guide or legal counsel for guidance on affiliated entities.

Which facility types are affected?

This requirement applies to manufacturers operating under any of the following facility classifications:

• Manufacturer — Contract
• Manufacturer — Contract & Direct Distributing
• Manufacturer — Own Label Warehouse
• Manufacturer — Traditional
• Manufacturer — Traditional & Self Distributing
• Manufacturer — Virtual

Which products are in scope?

The reporting requirement covers the following product and service categories:

• Active Pharmaceutical Ingredient (API) — Prescription (Rx)
• Drugs — Human OTC

Action steps for manufacturers

1. Review your drug portfolio for any NDCs with a WAC increase of 10% or more year-over-year
2. Confirm your entity qualifies as a reporting manufacturer under all three criteria
3. Register with the Oregon Drug Price Transparency Program if not already enrolled
4. Review the program's user guide for detailed calculation instructions
5. Submit your report no later than April 15, 2026

Oregon Drug Price Transparency Program — Official Resources

‍For registration, the user guide, and additional manufacturer resources, visit: https://dfr.oregon.gov/drugtransparency/pages/manufacturers.aspx

LighthouseAI Regulatory Monitoring

Stay up to date with all regulatory updates across the country.

LighthouseAI state licensing software offers automated surveillance capabilities that will send you notifications like these for all US states and jurisdictions.

Not only that, but they are tailored to your specific business activities and product portfolio. No more weeding through each and every regulation.

Only receive the notifications that are pertinent to you. Saving you hours of research time.

Contact us to learn more: Contact LighthouseAI

Join the LighthouseAI Mailing List

Receive additional news, trends, and insights about the US pharmaceutical supply chain from LighthouseAI.

‍Join the Mailing List